Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study

Fengxian Shen,Shiming Lu,Yibing Peng,Fan Yang,Yan Chen,Yingying Lin,Chen Yang,Li Wu,Huijun Li,Yijie Zheng
DOI: https://doi.org/10.1016/j.cca.2017.05.029
IF: 6.314
2017-01-01
Clinica Chimica Acta
Abstract:•The ROC-AUC of ROMA was significantly better than that of HE4 or CA 125 for all malignant ovarian tumors compared with benign diseases for all patients.•Roma combined with HE4 will increase the sensitivity.•This present study demonstrated the efficiency of HE4 and ROMA in the distinction of ovarian cancers from benign disease in a multiple-regions Chinese population, especially in premenopausal women.
What problem does this paper attempt to address?